Doris Duke Clinical Scientist Development Award
The purpose of the Doris Duke Clinical Scientist Development Award Program is to provide support formentored research to junior faculty members with an M.D. or M.D./Ph.D. (physician-scientists) workingin any disease area as they begin their careers as independent clinical researchers.The early stage of career development, when a researcher is transitioning from working in a mentor’slaboratory to setting up an independent research program and obtaining grant funding, is a criticalperiod. It is often more difficult for physician-scientists who are conducting clinical research to makethis transition than it is for other researchers because these individuals typically have to balance thedemands of seeing patients with those of conducting research. Those demands, together with thecomplexity of today’s research environment and the pace of progress, make it particularly challenging tomaintain the knowledge base needed to be both a clinician and a researcher. Nevertheless, the role of thephysician-scientist in providing the bridge between the clinic and the laboratory is critical for the timelytranslation of basic research findings into therapeutic approaches and for the transfer of clinicalknowledge back to the laboratory.
The 2009 Clinical Scientist Development Awards are being offered to eligible junior faculty members ata funding level of $135,000 per year for 3 years. It is DDCF’s hope that by providing stable support at acritical career juncture for physician-scientists, the Clinical Scientist Development Award willencourage physicians to pursue careers in clinical research.
Definition of Clinical ResearchFor the purposes of this award program, clinical research is defined as research conducted with humansubjects with direct application to the prevention, diagnosis, treatment, or cure of any human disease.The Foundation’s definition of clinical research includes:• Studies on the etiology and pathogenesis of human disease• Therapeutic interventions• Clinical trials• Epidemiological studies• Disease control research• Operations and implementation research
Eligibility of NomineeThis program is specifically intended to help physician-scientists make the critical transition fromtraining to independence as clinical investigators.It is the responsibility of each institution to ensure that its nominees meet all of the eligibilityrequirements. The replacement of nominees will not be permitted.Applicants must:• Be a physician-scientist conducting clinical research in any disease area;• Have received an M.D. or a foreign equivalent from an accredited institution;• Be working in a U.S. degree-granting institution, but do not have to be a U.S. citizen;• Have a full-time faculty level position not higher than the Assistant Professor level; and• Have been appointed to their first full-time faculty level position between January 1, 2004 andJanuary 1, 2009. (All full-time post-fellowship Instructor level positions will be considered full-timefaculty level appointments).
Online Submission of NominationsInstitutions nominating candidates must submit their nominations using the online system athttp://www.ddcf.org/apps/csda/index.asp on or before 5 pm EST on November 5, 2008. Before enteringthe online system, please be sure that you gather all the required information listed in the instructions fornomination which are available at http://www.ddcf.org/mrp-csda. All of an institution’s nominationsmust be entered at the same time. Nominations submitted by other methods will not be accepted. It is theresponsibility of the institutions to ensure that candidates nominated
American Laryngological Association/American Laryngological Voice and Research Education Foundation Award
The purpose of this award is to support basic, translational, or clinical research projects in laryngology,voice, outcomes, and related subjects.B. ELIGIBILITYCandidates for this award should be otolaryngologists who have completed their training at an ACGMEaccredited program in otolaryngology - head and neck surgery. The principal investigator should be aphysician faculty member of a recognized department, division, or section of otolaryngology-head andneck surgery. Previous ALA or AAO-HNS Foundation research grant recipients are eligible to compete forthis grant. However, candidates who have successfully obtained funding from a private or federal fundingagency for the same research are ineligible. Candidates who have applied for support of the sameresearch from other funding sources, and who are notified of an award from both another agency andfrom ALA must choose only one of the awards.C. CONDITIONSResearch supported by this award should be specifically directed toward the pathogenesis,pathophysiology, diagnosis, prevention, or treatment of diseases, disorders, or conditions of the larynxand may be either basic or clinical/translational in approach. While not specifically required, proposalswhich aim to introduce new knowledge and methodology from other disciplines to research in laryngologyor neurolaryngology, or which demonstrate collaborative effort with members of other related disciplinesare encouraged. Projects must be designed so as to yield useful information within the period of award,but priority will be given to projects that are also innovative with promise to develop into new long-rangeor expanded research programs capable of attracting funding from other sources. The grant applicationmust be accompanied by letters of support from the Chair of the candidate’s academic department.These letters are to indicate a general level of support of the applicant, and to demonstrate the fact thatthe Department will make time, space, and other resources accessible for completion of the project.D. TERMS1. Amount: $10,000 maximum. The foundation will consider requests to cover travel expenses up to$1000 for the principal investigator to present his/her results at the ALA annual meeting.2. Period: 12 months, non-renewable
All applicants must submit a Letter of Intent online no later than midnight Eastern Standard TimeDecember 15. The letter of intent includes the title of the project, the principal investigator, and anabstract of the work. This will facilitate planning review requirements.
American Head and Neck Society Alando J. Ballantyne Resident Research Pilot Grant
For the best grant application by a resident in the U.S. or Canada. One year, non-renewable, $10,000, one available annually.
The purpose of this award is to support basic, translational, or clinical research projects in head and neckoncology. Clinical or translational research studies are strongly encouraged and should be specificallyrelated to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neckneoplastic disease. The Alando J. Ballantyne Resident Research Pilot Grant memorializes Alando J.Ballantyne, M.D., a giving teacher, dedicated surgeon, and a devoted husband and father.ELIGIBILITYThis grant is open to resident in U.S. or Canadian training programs. Previous AHNS or AAO-HNSFoundation research grant recipients are eligible to compete for this grant. However, candidates whohave successfully obtained funding from a private or federal funding agency for the same research areineligible. Candidates who have applied for support of the same research from other funding sources, andwho are notified of an award from both another agency and from AHNS must choose only one of theawards.CONDITIONSResearch supported by this award should be specifically directed toward the pathogenesis,pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may beeither basic or clinical/translational in approach. While not specifically required, proposals which aim tointroduce new knowledge and methodology from other disciplines to research in head and neck disease,or which demonstrate collaborative effort with members of other related disciplines are encouraged.Projects must be designed so as to yield useful information within the period of award, but priority will begiven to projects that are also innovative with promise to develop into new long-range or expandedresearch programs capable of attracting funding from other sources. The grant application must beaccompanied by letters of support from the Chair of the candidate’s academic department and from theprincipal scientific advisor or mentor. These letters are to indicate a general level of support of theapplicant, the fact that the Department will make time, space, and other resources accessible forcompletion of the project, and that the applicant will have appropriate supervision/support throughout theperiod of the grant. Applicants must obtain letters of support/understanding from all key personnel on theproject.TERMS1. Amount: $10,000 maximum2. Period: 12 months, non-renewable
American Head and Neck Society Pilot Grant
Open to Medical Students, residents, PhD, and junior faculty residing in the U.S. and Canada to support basic, translational, or clinical research projects in head and neck oncology. One year, $10,000, one available annually.
The purpose of this award is to support basic, translational, or clinical research projects in head and neckoncology. Clinical or translational research studies are strongly encouraged and should be specificallyrelated to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neckneoplastic disease.ELIGIBILITYCandidates for this award should reside in the U.S. or Canada, be medical students, residents, Ph.D.s orfaculty members at the rank of associate professor or below. Previous AHNS or AAO-HNS Foundationresearch grant recipients are eligible to compete for this grant. However, candidates who havesuccessfully obtained funding from a private or federal funding agency for the same research areineligible. Candidates who have applied for support of the same research from other funding sources, andwho are notified of an award from both another agency and from AHNS must choose only one of theawards.CONDITIONSResearch supported by this award should be specifically directed toward the pathogenesis,pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may beeither basic or clinical/translational in approach. While not specifically required, proposals which aim tointroduce new knowledge and methodology from other disciplines to research in head and neck disease,or which demonstrate collaborative effort with members of other related disciplines are encouraged.Projects must be designed so as to yield useful information within the period of award, but priority will begiven to projects that are also innovative with promise to develop into new long-range or expandedresearch programs capable of attracting funding from other sources.The grant application must be accompanied by letters of support from the Chair of the candidate’sacademic department and from the principal scientific advisor or mentor. These letters are to indicate ageneral level of support of the applicant, the fact that the Department will make time, space, and otherresources accessible for completion of the project, and that the applicant will have appropriatesupervision/support throughout the period of the grant. Applicants must obtain letters ofsupport/understanding from all key personnel on the project.TERMS1. Amount: $10,000 maximum2. Period: One year, non-renewable
Visiting Scientist Award
The IARC is offering a Visiting Scientist Award for a qualified and experienced investigator with recent publications in international peer-reviewed scientific journals who wishes to spend from six to twelve months at the IARC working on a collaborative project in a research area related to the Agency's programmes: epidemiology, biostatistics, environmental chemical carcinogenesis, cancer etiology and prevention, infection and cancer, molecular cell biology, molecular genetics, molecular pathology and mechanisms of carcinogenesis.Candidates are requested to contact the relevant Scientific Groups in order to set up a collaborative project. For details on scientific programmes and research groups please consult the IARC Web site: http://www.iarc.fr/en/Research-Groups/Clusters-Groups, or contact the IARC at the address below.Applicants must belong to the staff of a university or a research institution and should provide written assurance of a post to return to at the end of the period of award.Deadline for receipt of applications is: 30 November 2008Candidates will be notified of the outcome of their application by the end of April 2009. There will be an annual remuneration of up to US$80,000-, which will take into account the on-going salary of the visiting scientist plus the cost of travel. The Award should be taken up no later than 30 November 2009.Fellowship application forms and more detailed information are available from:Fellowship ProgrammeINTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC)150 cours Albert-Thomas, 69008 Lyon, FranceTel: +33 (0)472 73 84 48; Fax: +33 (0)472 73 80 80; E-mail: vsa@iarc.fr
The Eli and Edythe Broad Foundation created the Broad Medical Research Program (BMRP) for Inflammatory Bowel Disease (IBD) Grants in 2001.IBD refers to two chronic inflammatory gastrointestinal disorders: Crohn's disease and ulcerative colitis. Although numerous scientific advances have been made in understanding and treating IBD, the precise cause, successful treatment and prevention of IBD remain unknown.The Eli and Edythe Broad Foundation, through the BMRP, provides 40 percent of all private funding for IBD research in the United States. Our approach is different than many traditional scientific and medical funding organizations. We fund early stage investigation – with the goal that innovative ideas need financial support for early testing to ultimately lead to effective treatment, diagnosis and prevention of IBD.The BMRP provides rapid funding to investigators working in non-profit organizations worldwide for up to two years for basic or clinical IBD research projects that: * Are innovative * Are in the early stages of exploration * Will improve the diagnosis, therapy or prevention of IBD in the near future; and * Will lead to longer-term funding by more traditional granting agenciesThe BMRP provides funding to generate pilot research data, rather than serving as the final grant source for a research project. Grantees are encouraged to generate sufficient preliminary data in the first year in order to compete successfully for continuation funding from us and/or other sources.A grantee may receive second-year funding from the BMRP if the researcher demonstrates maximal progress in the first year of the grant, validates the original research premise and demonstrates a clear need for additional preliminary data.Because we believe that great ideas could come from non-traditional sources, we encourage basic and clinical investigators and scientists not currently working in IBD and interdisciplinary teams to apply.
There is a two-step process for requesting funding from the Broad Medical Research Program (BMRP) for Inflammatory Bowel Disease:1. The first step is to submit a Letter of Interest. Instructions and format for Letters of Interest may be found under “How to Apply.” Decisions on Letters of Interest are based on external expert review of the proposal and usually are made within four to six weeks.2. If the BMRP is interested in pursuing a project, an invitation is extended to submit a full grant application. At that time, the grant application instructions and forms are sent to the Principal Investigator. Decisions on grant applications are made based on external review by subject experts and usually take eight to 10 weeks.There are no deadlines or specific dates for applications. Proposals are accepted and reviewed year-round. Revised proposals may only be submitted at the request of the BMRP.Special Requests for ProposalsThe BMRP is currently soliciting proposals in two areas of research:Differences in IBD incidence between developing and developed countriesThe BMRP is funding innovative research into the possible reasons for low and high incidence of IBD in different areas of the globe. Proposals should be exploratory in nature or designed as pilot. The research should shed light on factors that may influence low versus high global areas of prevalence of the disease. The research should ultimately be helpful in improved understanding of the etiology of IBD and the factors that enhance or prevent the genesis of the disease.IBD and Diabetes MellitusThe BMRP is interested in early stage exploratory innovative research proposals to investigate the similarities and differences between inflammatory bowel diseases (IBD) and diabetes mellitus (DM).Proposals should be exploratory in nature designed as pilot projects researching possible commonality in the etiopathogenesis between IBD and DM. Human or animal model studies are welcomed.
Fanconi Anemia Research Fund Program Announcement: Head And Neck Carcinogenesis Key Dates Release Date: July 1, 2008 Application Submission Date: Ongoing Peer Review Dates: Ongoing Earliest Anticipated Start Date: Ongoing Summary Fanconi anemia is a rare hereditary disease characterized by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS) and acute non-lymphocytic leukemia (AML), squamous cell carcinoma of the head and neck, and cellular hypersensitivity to cross linking agents. The function of the proteins is largely unknown, but many of them form complexes with each other and in one canonical “pathway” seven or eight of the known Fanconi anemia (FA) proteins bind together in a nuclear complex, a complex apparently required for the monoubiquitination of two of the three proteins not found in the core complex, FANCD2 and FANCI. Once this occurs, FANCD2 and FANCI translocate to damage-induced nuclear foci containing BRCA1, BRCA2 and Rad51. The functions of FANCD2 and FANCI in these nuclear complexes are unclear. Although more than 90% of the research in this field focuses on mechanisms of genotoxicity, a goal of the Fanconi Anemia Research Fund is to encourage investigative approaches dealing with the tissuespecific issues of the FA phenotype. Some have argued that because hypersensitivity to genotoxic stress is a feature of all somatic cells in FA, tissue-specific outcomes (specific epithelial malignancies and bone marrow failure, for example) are less likely to be related simply to genetic instability than to other functions of the protein. In fact, multiple biochemical functions have been ascribed to some of the FA proteins and, in some cases, these functions are cytoplasmic and not nuclear. The role of the Fanconi anemia proteins in protecting normal individuals against sporadic head and neck cancers is entirely unknown. The natural course of the disease in FA patients is unique. The onset of head and neck cancers in patients with Fanconi anemia (age 18-40) is decades earlier than in non-FA patients with this type of cancer and, unlike non-FA patients, the majority of such patients are neither tobacco smokers nor alcohol drinkers. The management of FA patients with this malignancy is also challenging. For example, FA patients may experience potentially lethal toxic effects from radiation and chemotherapy doses conventionally prescribed to patients with head and neck cancers. Therefore, clinical management is limited to surgical approaches and less-than-fully tested pharmacologic modalities that do not lead to DNA damage. This funding opportunity will use the investigator-initiated award mechanism to support work focused on the molecular pathogenesis, diagnosis, and treatment of head and neck squamous cell carcinoma in patients with FA. We expect that the nature and scope of the proposed research will vary from application to application. We expect that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received. Eligible Applications The goal of this initiative is to foster studies on the molecular pathogenesis, diagnosis and treatment of head and neck cancers in patients with Fanconi anemia. Applications focusing primarily on hematopoietic malignancies, bone marrow failure, developmental anomalies, endocrinopathies, or general functions of the FA proteins in DNA damage and repair responses will not be accepted for review under this RFA. Applications from the following will be considered: Eligible domestic and foreign institutions/organizations, including for-profit or nonprofit, public or private, units of state and local governments, and eligible agencies of the federal government. Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Applicants may submit only one application. Content and Form of Application Submission Applications must be prepared using the most current Fanconi Anemia Research Fund (Fund) research grant application instructions and forms.
Fanconi Anemia Research Fund, Inc. 1801 Willamette Street, Suite 200 Eugene, OR 97401 Telephone: 541-687-4658 Family Support Toll-Free Line (in United States): 1-888-FANCONI (888-326-2664) Fax: 541-687-0548 E-mail: info@fanconi.org
Dermatopathology GrantThe grant provides financial support for dermatopathology research projects thatbenefit the specialty of dermatology.Applicant Eligibility Requirements:• M.D.; Ph.D.; M.D., Ph.D.; or D.O. degree• Dermatologist or pathologist who will have completed a dermatopathologyfellowship in a division or department of dermatology, pathology ordermatopathology at the time of funding, and is attempting to embark on aresearch career. Research proposals may include bench research, classicalepidemiology, outcomes analysis or other approaches and should be clearlyrelated to advancing the field of dermatopathology• Investigator in the early stages of career
To meet the application deadline, can my application be postmarked by October 15th?No. To be considered for a 2009 research award, your complete research application must besent so that it is RECEIVED at the Foundation office on or before Wednesday, October 15,2008. Your application should be sent to the following address:Medical and Scientific CommitteeDermatology Foundation1560 Sherman Avenue, Suite 870Evanston, IL 60201-4808
12next